Puma, Evotec, and Globex Mining: INSIDER ALERT and BUY RECOMMENDATION!

Globex Mining: When will the stock break out?

Globex Mining continues to offer an attractive entry opportunity: Since April, the share has been trading sideways between EUR 0.80 and EUR 0.90. At the same time, the news flow from the mining incubator remains consistently positive. The Company operates similarly to an active resource-focused investment fund, with exposure to over 250 projects across North America – about half of which are in the precious metals sector (including gold, silver, platinum, and palladium). This structure provides investors with broad risk diversification. The capital-intensive exploration is not carried out by Globex, but by specialized companies. In return, Globex receives a mix of upfront payments, equity interests, milestone-based payments, and royalties.

Due to the large number of projects, there is also a regular news flow, which is unusual for exploration companies. Most recently, positive drilling results were reported by partner Antimony Resources. Further high-grade antimony intersections were found during drilling on the Bald Hill property in New Brunswick, Canada. Drill hole BH-25-05 returned 1.1% antimony (Sb) over 14.5 meters at a depth of 108.8 m to 123.3 m. Drill hole BH-25-08 returned 14.91% antimony (Sb) over 3.0 meters at a depth of 88.8 m to 91.8 m, including massive stibnite. Drill hole BH-25-09 returned 9.85% antimony (Sb) over 4.3 meters at a depth of 103.6 m to 107.9 m. The reported drill hole intersections are estimated to represent 75% to 80% of true thickness.

There is also news from the gold portfolio. Globex Mining has acquired a project in the northern part of a historically significant gold basin mining district in the US state of Arizona. The property comprises 40 lode claims covering a total area of 334.45 hectares and is located in Mohave County, approximately 85 km southeast of Las Vegas. Gold was first discovered in this district in the early 1870s.

https://youtu.be/rRnoU3E5onY?si=BNNizjKLQRWNuSg0

Puma: Insider buying and analysts recommend buying

While Globex continues to impress with a steady stream of positive news, Puma shocked shareholders in July with yet another profit warning. The share price plummeted from over EUR 24 to almost EUR 17. And this was not the first piece of bad news this year - at the end of 2024, the sporting goods manufacturer's share price was still trading above EUR 46. With the new management board now in place, is it time to get in? Analyst opinions and insider purchases at least suggest that a bottom may have been reached.

The most recent insider purchase was reported by Arthur Hoeld. According to the report, the Puma executive board member purchased a derivative on the share worth EUR 101,000 on August 7. A few days earlier, he had already bought shares worth over EUR 100,000 at a price of EUR 19.0455.

If the analysts at Berenberg are right, Hoeld would be making a good deal. The experts see the fair value of Puma shares at EUR 40. After talks with management, they were convinced of the Company's potential and, in particular, the strength of the brand. Even though the turnaround will take time and is not without risks, they recommend buying Puma shares.

Evotec: No sign of insider buying

While insider buying is giving cause for hope at Puma, there is a lack of such activity at Evotec. No insider has bought shares since February of this year. The share price has fallen from EUR 9 to EUR 6, and a new strategy has been announced. Do the Executive Board and Supervisory Board no longer believe in their vision? It is at least permissible to entertain this thought.

When the half-year figures were published, CEO Dr. Christian Wojczewski was certainly optimistic, stating: "We are on the right track with the implementation of our strategy: Evotec is making significant progress toward sustainable and profitable growth. Just – Evotec Biologics continued its strong growth trajectory with revenues exceeding EUR 100 million in the first half of the year, and the development of our strategic partnership with Sandoz is proof of the Company's promising future as a scalable technology provider with a more capital-efficient model. Our core D&PD business continues to face weak demand, but we are seeing strong progress in our key collaborations and are systematically expanding our platform technologies, such as our molecular patient database. I am confident that our continued focus on our leadership in technology and science will continue to deliver tangible results in the future." Why doesn't Wojczewski buy Evotec shares then? This would certainly strengthen confidence in the new strategy.

Analysts are divided on Evotec's prospects. According to marketscreener.com, there are no sell recommendations, and 6 out of 8 analysts recommend buying the biotech company's stock, but the price targets vary widely. While the Evotec bears at Deutsche Bank consider the share to be fairly valued at EUR 6, the experts at RBC believe EUR 11.90 is possible. According to marketscreener.com, there is also a price target of EUR 22. However, this is likely to be a database error, or the analysis firm has quietly discontinued its coverage in the meantime. In any case, there has been no price target at this level in recent months.

Globex is an exciting stock for those looking to get involved in exploration opportunities in the commodities sector. The Company is broadly positioned, debt-free and is buying back its own shares. It is only a matter of time before it breaks out of its sideways channel. When Puma will recover, however, is uncertain. The brand undoubtedly has appeal, but it is not a foregone conclusion that the turnaround will be as rapid as Adidas' in 2022. Evotec is an interesting comeback candidate, but analysts and investors will likely have to get used to the new strategy focusing on earnings before growth.